The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”

In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate & improve their illness.

Getting the best available treatment for the lowest price is a no brainer.

We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.

They're FDA approved, have the best in class treatment, and is more affordable than the others.

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

$TGTX possibly the best therapy available for MS patients that exists today!